Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: An analysis from the NCCN NHL Database

Blood

Volumn 119, Issue 9, 2012, Pages 2093-2099

  LaCasce, Ann S ^a   Vandergrift, Jonathan L ^b   Rodriguez, Maria A ^c   Abel, Gregory A ^a   Crosby, Allison L ^a   Czuczman, Myron S ^d   Nademanee, Auayporn P ^e   Blayney, Douglas W ^f   Gordon, Leo I ^g   Millenson, Michael ^h   Vanderplas, Ann ^e   Lepisto, Eva M ^b   Zelenetz, Andrew D ⁱ   Niland, Joyce ^e   Friedberg, Jonathan W ^j  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b National Comprehensive Cancer Network   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^f STANFORD CANCER INSTITUTE   (United States)

^g NORTHWESTERN UNIVERSITY   (United States)

^h FOX CHASE CANCER CENTER   (United States)

ⁱ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^j UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; RITUXIMAB; VINCRISTINE;

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CENTER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COMPARATIVE EFFECTIVENESS; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; UNSPECIFIED SIDE EFFECT;

EID: 84857748460     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-07-369629     Document Type: Article

References (23)

1. Herrmann A, Hoster E, Zwingers T, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol. 2009;27(4):511.
2. Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol. 2005;23(9):1984-1992. (Pubitemid 46211378)
3. Howard OM, Gribben JG, Neuberg DS, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol. 2002;20(5):1288-1294. (Pubitemid 34177435)
4. National Comprehensive Cancer Network Inc. NCCN Non Hodgkin's Lymphoma Clinical Practice Guidelines in Oncology. 2010. NCCN Web site. http://www.nccn.org. Accessed May 18, 2010.
5. Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol. 2005;23(28):7013-7023.
6. Damon LE, Johnson JL, Niedzwiecki D, et al. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantlecell lymphoma: CALGB 59909. J Clin Oncol. 2009;27(36):6101-6108.
7. Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progressionfree survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005;105(7):2677-2684. (Pubitemid 40450320)
8. Geisler CH, Kolstad A, Laurell A, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood. 2008;112(7):2687-2693.
9. Kho ME, Lepisto EM, Niland JC, et al. Reliability of staging, prognosis, and comorbidity data collection in the National Comprehensive Cancer Network (NCCN) non-Hodgkin lymphoma (NHL) multicenter outcomes database. Cancer. 2008; 113(11):3209-3212.
10. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329(14):987-994.
11. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383. (Pubitemid 17055592)
12. Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111(2):558-565.
13. Romaguera JE, Fayad LE, Feng L, et al. Ten-year follow-up after intense chemoimmunotherapy with rituximab-HyperCVAD alternating with rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol. 2010;150(2):200-208.
14. Geisler CH, Kolstad A, Laurell A, et al. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood. 2010;115(8):1530-1533.
15. Determann O, Hoster E, Ott G, et al. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood. 2008; 111(4):2385-2387. (Pubitemid 351451450)
16. Katzenberger T, Petzoldt C, Holler S, et al. The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma. Blood. 2006;107(8):3407.
17. Martin P, Chadburn A, Christos P, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol. 2009;27(8):1209-1213.
18. Martin P, Chadburn A, Christos P, et al. Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies. Ann Oncol. 2008;19(7):1327-1330.
19. Epner EM, Unger J, Miller T, et al. A multi center trial of hyperCVAD + Rituxan in patients with newly diagnosed mantle cell lymphoma. Blood. 2007;110(11):387.
20. Budde LE, Guthrie KA, Till BG, et al. Mantle Cell Lymphoma International Prognostic Index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stemcell transplantation. J Clin Oncol. 2011;29(22): 3023-3029.
21. Hermine O, Hoster E, Walewski J, et al. Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) is superior to 6 courses CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: results of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net) [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116(21):Abstract 110.
22. Kluin-Nelemans JC, Hoster E, Walewski J, et al. R-CHOP versus R-FC followed by maintenance with rituximab versus interferon-alfa: outcome of the first randomized trial for elderly patients with mantle cell lymphoma [abstract]. Blood (ASH Annual Meeting Abstracts). Blood. 2011;118(21): Abstract 439.
23. FDA. Guidance for Industry Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics, 2007. Food and Drug Administration Web site. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM071590.pdf. Accessed May 18, 2010.